VB4-845

a phase I clinical study of intratumorally administered VB4-845, an anti-epithelial cell adhesion molecule recombinant fusion protein, in patients with squamous cell carcinoma of the head and neck

Networked: 7 relevant articles (0 outcomes, 3 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Cizeau, Jeannick: 4 articles (07/2011 - 02/2009)
2.	Entwistle, Joycelyn: 4 articles (07/2011 - 02/2009)
3.	MacDonald, Glen C: 4 articles (07/2011 - 02/2009)
4.	Kowalski, Mark: 2 articles (11/2010 - 02/2009)
5.	Bosc, Denis: 2 articles (08/2009 - 02/2009)
6.	Spearman, Maureen: 2 articles (08/2009 - 02/2009)
7.	Arii, Shigeki: 1 article (04/2014)
8.	Ban, Daisuke: 1 article (04/2014)
9.	Irie, Takumi: 1 article (04/2014)
10.	Kudo, Atsushi: 1 article (04/2014)

Related Diseases

1.	Squamous Cell Carcinoma of Head and Neck 02/06/2009 - "A phase I trial was conducted to determine the maximum tolerated dose (MTD) of VB4-845 when administered as weekly intratumoral (IT) injections to patients with squamous cell carcinoma of the head and neck (SCCHN). " 01/01/2009 - "Twenty-four patients with advanced, recurrent squamous cell carcinoma of the head and neck received two cycles of five daily intratumoral VB4-845 injections of 20, 40, 80, 130, 200, or 280 microg. " 04/01/2008 - "VB4-845 is currently undergoing phase II and III clinical trials in patients with head and neck squamous cell carcinomas, as well as phase II clinical trials for the treatment of superficial transitional cell carcinoma of the bladder." 01/01/2009 - "A phase I clinical study of intratumorally administered VB4-845, an anti-epithelial cell adhesion molecule recombinant fusion protein, in patients with squamous cell carcinoma of the head and neck."
2.	Urinary Bladder Neoplasms (Bladder Cancer) 11/15/2010 - "A Phase I dose-escalation study was performed to determine the maximum tolerated dose (MTD) of the immunotoxin VB4-845 in patients with nonmuscle-invasive bladder cancer (NMIBC) refractory to or intolerant of bacillus Calmette-Guerin (BCG). " 04/01/2008 - "VB4-845, a conjugated recombinant antibody and immunotoxin for head and neck cancer and bladder cancer." 04/01/2008 - "Viventia Biotech Inc, under license from the University of Zurich, is developing VB4-845, comprising a Pseudomonas exotoxin fused to an anti-epithelial cell adhesion molecule single-chain antibody fragment, for the potential treatment of head and neck cancer (intratumoral) and bladder cancer (intravesical). "
3.	Non-Muscle Invasive Bladder Neoplasms 11/15/2010 - "Although an MTD was not determined at the doses administered, VB4-845 showed evidence of an antitumor effect that warrants further clinical investigation for the treatment of NMIBC in this patient population." 07/01/2011 - "VB4-845, purified from TB fed-batch fermentation, showed clinical efficacy when administered locally to treat non-muscle invasive bladder cancer (NMIBC) and squamous cell carcinomas of the head and neck (SCCHN). " 11/15/2010 - "A Phase I dose-escalation study was performed to determine the maximum tolerated dose (MTD) of the immunotoxin VB4-845 in patients with nonmuscle-invasive bladder cancer (NMIBC) refractory to or intolerant of bacillus Calmette-Guerin (BCG). "
4.	Transitional Cell Carcinoma 04/01/2008 - "VB4-845 is currently undergoing phase II and III clinical trials in patients with head and neck squamous cell carcinomas, as well as phase II clinical trials for the treatment of superficial transitional cell carcinoma of the bladder."
5.	Neoplasms (Cancer) 08/01/2009 - "These results argue that the local administration of VB4-845 has advantages with respect to safety over systemic administration and may be an effective alternative method for targeting those cancers that are amenable to local routes of administration." 04/01/2014 - "In subcutaneous xenograft models, the combination of VB4-845 plus 5-FU showed significant regression of tumors compared with the control (p = 0.016). " 01/01/2009 - "VB4-845 reduced or stabilized tumors in 71.4% of epithelial cell adhesion molecule-positive patients. "

Related Drugs and Biologics

1.	Immunotoxins (Immunotoxin)
2.	Epithelial Cell Adhesion Molecule
3.	Recombinant Fusion Proteins
4.	Immunoglobulin Fragments
5.	Fluorouracil (Carac)
6.	Exotoxins
7.	Enzymes

Related Therapies and Procedures

1.	Injections
2.	Therapeutics